Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: DanZ who wrote (1828)	12/6/1999 5:53:00 PM
From: Mad2	Read Replies (1) \| Respond to of 5582

Dan GUMM is below its 50 day MA.....that coupled with the story loosing it's luster (ie Zicam) and the increased registration of stock all point downward. That's my view By the way, does this mean you are not as confident as me as to where GUMM is headed?....... I will not accept your challenge based on the stock price but I will accept it based on fundamental factors such as sales or acceptance of the second study for Zicam by a reputable medical journal. Those are after all, the issues being debated. Frankly I'm not interested in the story (Zicam) as the appeal of the story is seasonal anyway, besides with all the FTC attention surrounding QGLY I would seriously question if GUMM will be able to differentiate themselves from QGLY in terms of claimes. Add to that the fact that a nasel application isn't as consumer friendly as pill or lozenges which are heavily promoted by large consumer products companies and you have a product with limited marketability attempting to gain consumer acceptance in a very crowded field. In closing GUMM will at best bounce around the low teens with the possibility of a spike here and there.......but I'm confident it will see single digits in a matter of months (or possibly earlier...one never knows). Mad2